Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis

Zhang, Jin; Jiang, Yuanyuan; Wang, Xiaoxia; Wang, Haiping; Chen, Huan; Wu, Yichao; Wang, Long; Xiang, Ping; Yue, Guizhou; Zhang, Li

doi:10.21037/atm-20-5741

Cited by 30 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Originally, danshen acted in cardiovascular and cerebrovascular diseases because it facilitates blood circulation and stasis clearance [27,28]. However, accumulating evidences have declaimed the additional efficacy of danshen in treating many types of cancer by its blockage of cancer growth and metastasis [18,20,22,[29][30][31][32][33][34][35][36]. In support of these pre-existing studies, our data reveal similar benefits of danshen for HNSCCs, cancers for which danshen's therapeutic effects have not been extensively investigated.…”

Section: Discussionsupporting

confidence: 79%

Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas

Hsu

Yang

Tsai

et al. 2021

IJMS

View full text Add to dashboard Cite

Head and neck squamous cell carcinomas (HNSCCs) are the most common cancers of the head and neck, and their prevalence is rapidly increasing. HNSCCs present a clinical challenge because of their high recurrence rate, therapeutic resistance to radiation and chemotherapy drugs, and adverse effects. Hence, traditional Chinese herbal treatment may be advantageous to therapeutic strategies for HNSCCs. Danshen (Salvia miltiorrhiza), a well-known Chinese herb, has been extensively applied in treatments for various diseases, including cancer, because of its high degree of safety and low rate of adverse effects despite its unclear mechanism. Thus, we aimed to explore the possible anticancer effects and mechanisms of dihydroisotanshinone I (DT), a compound in danshen (extract from danshen), on HNSCCs. Three HNSCCs cell lines were used for in vitro studies, and a Detroit 562 xenograft mouse model was chosen for in vivo studies. Our in vitro results showed that DT could initiate apoptosis, resulting in cell death, and the p38 signaling partially regulated DT-initiated cell apoptosis in the Detroit 562 model. In the xenograft mouse model, DT reduced tumor size with no obvious adverse effect of hepatotoxicity. The present study suggests that DT is a promising novel candidate for anti-HNSCCs therapy.

show abstract

Section: Discussionsupporting

confidence: 79%

Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas

Hsu

Yang

Tsai

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…THSWD combined with chemotherapy can effectively reduce serum VEGF levels and lymphatic vessel density in breast cancer patients, thereby blocking angiogenesis and inhibiting tumor growth and metastasis, but its mechanism of action is still unclear [ 80 , 81 ]. Existing clinical studies have also shown that THSWD can inhibit angiogenesis and endothelial cell proliferation, reduce tumor microvessel density, prevent the binding of VEGF and its receptor, and down-regulate serum MVD and VEGF-A in patients after surgery [ 82 , 83 ].…”

Section: Discussionmentioning

confidence: 99%

Traditional Chinese Medicine for adjuvant treatment of breast cancer: Taohong Siwu Decoction

Jiang

et al. 2021

Chin Med

View full text Add to dashboard Cite

The high incidence of breast cancer is the greastest threat to women’ health all over the world. Among them, HER-2 positive breast cancer has the characteristics of high malignancy, easy recurrence and metastasis, and poor prognosis. Traditional Chinese medicine (TCM) has a rich theoretical basis and clinical application for breast cancer. TCM believes that blood stasis syndrome is one of the important pathogenesis of breast formation and development. Taohong Siwu Decoction (TSHWD) is based on the “First Prescription of Gynecology” Siwu Decoction. It is widely used in various blood stasis and blood deficiency syndromes, mainly in gynecological blood stasis. Clinical studies have found that THSWD can treat breast cancer by reducing blood vessel and lymphangiogenesis with auxiliary chemotherapy. In this study, we aim to explore the material basis and mechanism of THSWD in the treatment of HER-2 positive breast cancer through literature review and network pharmacology studies. Through a literature review of the traditional application, chemical composition of Chinese herbal medicine of THSWD, as well as its clinical reports and pharmacological research on breast cancer treatment. Meanwhile, we conducted “component-pathway-target” network through network pharmacology reveals the main material basis, possible targets and pathways of THSWD in inhibiting HER-2 positive breast cancer. Literature review and network pharmacology research results had predicted that, baicalein, kaempferol, caffeic acid, amygdalin, quercetin, ferulic acid, gallic acid, catalpol, hydroxysafflor yellow A, paeoniflorin in THSWD are the main effective chemical composition. THSWD regulates 386 protein targets and 166 pathways related to breast cancer. The molecular mechanism is mainly to improve the microenvironment of tumor cells, regulate the process of tumor cell EMT, and inhibit tumor cell proliferation and metastasis. This study revealed the mechanism of action of THSWD in the treatment of HER-2 positive breast cancer through literature review and network pharmacology studies, providing a scientific basis for clinical application.

show abstract

“…Other studies showed that tanshinone IIA has a growth inhibitory effect by inducing cell apoptosis and downregulating survivin expression in ovarian cancer cells ( Jiao and Wen, 2011 ; Li N. et al, 2018 ). Our studies showed that tanshinone IIA inhibits the growth of ovarian cancer cells in a dose-dependent manner by inducing G2/M phase arrest and cell apoptosis ( Zhou et al, 2020c ). In ovarian cancer, tanshinone IA significantly suppresses cell proliferation in vitro and tumor growth in vivo by inducing apoptosis and promoting autophagy via the inactivation of the PI3K/AKT/mTOR pathway in ovarian cancer ( Zhou et al, 2020a ).…”

Section: Tanshinones Inhibit Cell Proliferationmentioning

confidence: 88%

“…In ovarian cancer, Zhou et al found that tanshinone IIA inhibits the migration of A2780 and ID-8 ovarian cancer cells by inhibiting focal adhesion kinase phosphorylation ( Zhou et al, 2020c ). Another bioactive component, namely, cryptotanshinone, can suppress migration and invasion of ovarian cancer A2780 cells by dramatically inhibiting MMP-2 and MMP-9 expression ( Jiang et al, 2017 ).…”

Section: Tanshinones Block Metastasis Phenotypementioning

confidence: 99%

Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer

Zhou

Peng

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Female breast cancer, ovarian cancer, cervical cancer, and endometrial cancer are the most common tumors and the most common causes of cancer-related mortality worldwide in women. Drugs derived from natural plants play important roles in malignant tumor therapy. Salvia miltiorrhiza is a commonly used Chinese herb which has been used in the treatment of liver diseases and cardiovascular diseases because of its positive effect of promoting blood circulation, increasing oxidative stress, and removing blood stasis. Recently, studies have found that fat-soluble components of Salvia miltiorrhiza such as tanshinone II, tanshinone I, cryptotanshinone, and dihydrotanshinone I displayed good antitumor activity in vivo and in vitro for gynecological cancer by different molecular mechanisms. In this study, the latest research progress on the antitumor effect and mechanism of tanshinone compounds in breast cancer and gynecological cancer was reviewed to provide references for the research and clinical application of these compounds (tanshinone II, tanshinone I, cryptotanshinone, and dihydrotanshinone I).

show abstract

Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis

Cited by 30 publications

References 38 publications

Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas

Dihydroisotanshinone I as a Treatment Option for Head and Neck Squamous Cell Carcinomas

Traditional Chinese Medicine for adjuvant treatment of breast cancer: Taohong Siwu Decoction

Anticancer Effect of Tanshinones on Female Breast Cancer and Gynecological Cancer

Contact Info

Product

Resources

About